Featured Research

from universities, journals, and other organizations

Fighting Leukemia: Regimen Of Three Chemotherapy Drugs Shows Promise

Date:
December 11, 2006
Source:
Mayo Clinic
Summary:
Mayo Clinic Cancer Center, working in collaboration with Ohio State University Comprehensive Cancer Center, presented evidence Sunday that a novel regimen of three chemotherapy drugs -- pentostatin, cyclophosphamide and rituximab -- resulted in significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL).

Mayo Clinic Cancer Center, working in collaboration with Ohio State University Comprehensive Cancer Center, presented evidence Sunday that a novel regimen of three chemotherapy drugs -- pentostatin, cyclophosphamide and rituximab -- resulted in significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL). Lead researcher and Mayo Clinic hematologist Neil E. Kay, M.D., presented these findings at the 2006 American Society of Hematology Annual Meeting in Orlando.

"Chronic lymphocytic leukemia is incurable, but continues to be made more manageable with the advent of powerful new chemoimmunotherapy tools," says Dr. Kay. "We and our collaborators at Ohio State University, in particular Dr. Michael Grever, have done previous research on pentostatin that led us to believe there would be success with this regimen, and are pleased with the results."

Regimens using rituximab are common for CLL patients, says Dr. Kay, and his team decided to build upon that knowledge and their understanding of the highly potent chemotherapeutic antibiotic pentostatin to try to develop an even better treatment option. The investigators initiated a trial of three weeks (one cycle) of combined chemotherapy drugs pentostatin (P), cyclophosphamide (C) and rituximab (R) repeated in six cycles for 64 symptomatic but previously untreated patients. Patients in the study also received one year of prophylactic sulfamethoxazole-trimethoprim (anti-infection drug) and acyclovir (antiviral drug) along with the PCR treatment.

The researchers reviewed study participants' prognostic status and divided the patients into risk categories at the beginning of the study, using a number of different prognostic evaluation tools to describe them, including the Rai stages (clinical levels of disease progression), CD38 and ZAP-70 (overexpressed proteins found in CLL cells), IgVH (mutational status of the immunoglobulin gene occurring in CLL patients), and FISH panel assessments (fluorescent probes on the chromosomes to determine common recurring genetic mutations in CLL). The majority of the patients were in high-risk categories; they had significant disease progression and/or a high expectation of rapid advancement of disease.

Following treatment, Dr. Kay's team found that 91 percent of the patients experienced positive clinical responses (experienced improvement in their condition) to the treatment based on the National Cancer Institute's Working Group criteria for responses. Forty-one percent achieved complete response, 22 percent experienced nodular partial response and 28 percent partial response, with the average patient's disease currently estimated to being in response for 32.6 months. The researchers also found that bone marrow suppression and/or infections were minimal.

The prognostic variables that normally indicate likelihood of poor response to treatment appeared to be negated by the treatment --only one genetic defect (deletion of the p arm of chromosome 17) was found to prevent complete response or nodular partial response; the other risk factors did not diminish treatment effectiveness. Also, the researchers found that the regimen was equally effective in young and elderly (over age 70) patients.

"We are very pleased with the results of this study," says Dr. Kay. "This is a new, viable option for high-risk patients who might not have had much hope before, and it's especially exciting that it works for patients of all age groups."

Chronic lymphocytic leukemia is a blood and bone marrow cancer that affects 10,000 new patients each year in the United States. It is called chronic leukemia because it progresses more slowly than acute leukemia, and lymphocytic because it affects a group of white blood cells (lymphocytes), an important component of the immune system which typically fights infection.

Other Mayo Clinic researchers who collaborated on this research included Susan Geyer, Ph.D.; Timothy Call, M.D.; Tait Shanafelt, M.D.; Clive Zent, M.D.; Diane Jelinek, Ph.D.; Renee Tschumper; Nancy Bone; and Gordon Dewald, Ph.D. Collaborators from Ohio State University included Michael Grever, M.D.; John Byrd, M.D.; Thomas Lin, M.D., Ph.D.; Nyla Heerema, Ph.D.; and Laura Smith, Ph.D.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Fighting Leukemia: Regimen Of Three Chemotherapy Drugs Shows Promise." ScienceDaily. ScienceDaily, 11 December 2006. <www.sciencedaily.com/releases/2006/12/061211092616.htm>.
Mayo Clinic. (2006, December 11). Fighting Leukemia: Regimen Of Three Chemotherapy Drugs Shows Promise. ScienceDaily. Retrieved April 21, 2014 from www.sciencedaily.com/releases/2006/12/061211092616.htm
Mayo Clinic. "Fighting Leukemia: Regimen Of Three Chemotherapy Drugs Shows Promise." ScienceDaily. www.sciencedaily.com/releases/2006/12/061211092616.htm (accessed April 21, 2014).

Share This



More Health & Medicine News

Monday, April 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Breakfast Foods Are Getting Pricier

Breakfast Foods Are Getting Pricier

AP (Apr. 21, 2014) Breakfast is now being served with a side of sticker shock. The cost of morning staples like bacon, coffee and orange juice is on the rise because of global supply problems. (April 21) Video provided by AP
Powered by NewsLook.com
Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins